There are many holy grails in healthcare: addressing interoperability, achieving health equity, and universal patient records. Grail, a Menlo Park, Calif.-based liquid biopsy company, is working on another equally challenging task: ensuring fewer people die from cancer.
Last June, the company introduced Galleri, a test that screens patients for more than 50 cancers. A year later, the company is working with health systems to build a testing database and enroll 20,000 clinical study participants in a clinical study to gain access to U.S. food and Drug Administration approval. official.He details the plans AWS‘ Thursday virtual meeting For healthcare and life science innovation.
Next-generation sequencing company Illumina spun out The Holy Grail and the Holy Grail in 2016 archive 2020 IPO. The two companies re-merged last August, when Illumina completed its acquisition of Grail. Through its various stages of ownership, the Silicon Valley-based company has always had a clear mission: to develop a cancer detection test that can perform accurately and screen for all kinds of diseases.
Holy Grail gallery The test analyzes a blood sample to detect signals that indicate the presence of cancer. If cancer is found, the test’s results can show clinicians where the cancer originated in a patient’s body with 89 percent accuracy, Alag said.
In the company’s 2020 IPO filing, Grail said it would apply for approval of the test as early as 2023. To prepare the data for this review, the company is currently enrolling patients in a study aimed at enrolling 20,000 demographically diverse participants through North American health systems. The trial is designed to help Grail improve its technology and expand its dataset, which focuses on more than 30 million regions of the genome associated with oncogenic epigenetic and methylation factors.
The test is designed to be used in people at higher risk for cancer, such as those 50 years and older. Currently, patients can only be tested through Grail’s partner health systems, medical practices and self-insured employers. It costs $949 and requires a prescription.
Providence Is the first health system partner for the Galleri test.Health System in Renton, WA fusion The test was incorporated into clinical care last year to help Grail evaluate the tool’s efficacy and build its dataset.New Orleans two weeks ago Oxner Health Announced that it will offer the Galleri test to its patients as an addition to the recommended single cancer screening.
This most recommended screenings It is used in the United States for breast, lung, colon, prostate and cervical cancer. Adding the Galleri test to these recommended screenings could potentially avert 100,000 cancer-related deaths each year, Alag said.If his claims are true, the test could be dropping 71% of cancer deaths Caused by cancer for which screening is not recommended.
“We not only need to screen individuals for cancer, we need to screen individuals for cancer,” he said.
Credit: Meletios Verras, Getty Images
